WebOct 7, 2024 · The FDA has granted a priority review to a new drug application (NDA) for selinexor for the treatment of patients with penta-refractory multiple myeloma, according to Karyopharm Therapeutics, the ... WebFDA granted selinexor accelerated approval in 2024 in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who received at...
(PDF) Selinexor—A Drug Review - ResearchGate
WebDec 7, 2024 · Overexpression of Exportin-1 (XPO1), a key regulator of nuclear-to-cytoplasmic transport, is associated with inferior patient outcomes across a range of adult malignancies. Targeting XPO1 with selinexor has demonstrated promising results in clinical trials, leading to FDA approval of its use for multiple relapsed/refractory cancers. However, XPO1 … WebIn June 2024, the U.S. Food and Drug Administration granted accelerated approval to selinexor for the treatment of adult patients with relapsed or refractory diffuse large B … furniture store marshall texas
XPOVIO (Selinexor) Risk Assessment and Risk …
WebSelinexor (in combination with dexamethasone) received accelerated approval in the USA in July 2024 for the treatment of adult patients with relapsed or refractory multiple … WebFeb 26, 2024 · Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound manufactured by Karyopharm Therapeutics. ODAC's decision is based on a review of data from the phase IIb STORM (Selinexor Treatment of Refractory Myeloma) Part 2 study, which evaluated the drug in combination with low-dose dexamethasone in … WebJun 15, 2024 · The FDA review team deemed the risks and overall benefit/risk profile of selinexor to be acceptable for the DLBCL indication (Table 5). Continued approval for this … git username is not defined intellij